This document is a publication of a European patent application (EP4630060A1) for a specific antibody treatment for melanoma. The publication details the applicants (Julius-Maximilians-Universität Würzburg and Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.) and inventors, along with International Patent Classification codes related to medicinal preparations and cancer treatment.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on companies. However, it signifies potential future developments in melanoma treatment and may impact intellectual property landscapes for pharmaceutical and biotechnology firms operating within the designated European states. Companies involved in oncology research or antibody development should note this publication for competitive intelligence and R&D strategy.